fruquintinib Fruzaqla
Selected indexed studies
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. (Lancet, 2023) [PMID:37331369]
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. (JAMA, 2018) [PMID:29946728]
- ** (, 2024) [PMID:39869748]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. (2023) pubmed
- Fruquintinib. (2006) pubmed
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. (2018) pubmed
- Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. (2024) pubmed
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. (2025) pubmed
- Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. (2025) pubmed
- PMID:39869748 (2024) pubmed
- Fruquintinib (Fruzaqla) for metastatic colorectal cancer. (2024) pubmed
- PMID:40424426 (2025) pubmed
- FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. (2021) pubmed